XESSA



Trademark Coverage

No Class Specified

Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke

Owner

Affymax Pharma Limited

Business in London EC2A 2RS, GB

Owns 21 trademarks

Timeline
  • May 11
    2012
    Death Of International Registration
  • Jul 24
    2011
    Notification Processed By IB
  • Apr 14
    2011
    Final Disposition Notice Sent To IB
  • Apr 14
    2011
    Final Disposition Processed
  • Mar 24
    2011
    Grant Of Protection Created, To Be Sent To IB
  • Feb 22
    2011
    Registered Principal Register
  • Dec 07
    2010
    Published For Opposition
  • Dec 02
    2010
    Attorney Revoked And/Or Appointed
  • Dec 02
    2010
    TEAS Revoke/Appoint Attorney Received
  • Nov 17
    2010
    Notice Of Publication
  • Nov 02
    2010
    Law Office Publication Review Completed
  • Nov 02
    2010
    Assigned To LIE
  • Oct 19
    2010
    Approved For PUB Principal Register
  • Oct 19
    2010
    Application Filing Receipt Mailed
  • Oct 15
    2010
    Assigned To Examiner
  • Oct 15
    2010
    New Application Office Supplied Data Entered In TRAM
  • Oct 14
    2010
    SN Assigned For SECT 66 A APPL From IB